AU2001250420A1 - Pharmaceutical compositions - Google Patents

Pharmaceutical compositions

Info

Publication number
AU2001250420A1
AU2001250420A1 AU2001250420A AU5042001A AU2001250420A1 AU 2001250420 A1 AU2001250420 A1 AU 2001250420A1 AU 2001250420 A AU2001250420 A AU 2001250420A AU 5042001 A AU5042001 A AU 5042001A AU 2001250420 A1 AU2001250420 A1 AU 2001250420A1
Authority
AU
Australia
Prior art keywords
pharmaceutical compositions
pharmaceutical
compositions
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU2001250420A
Inventor
Michael Ambuhl
Barbara Haeberlin
Olivier Lambert
Barbara Luckel
Laurent Marchal
Armin Meinzer
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Novartis AG
Original Assignee
Novartis AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novartis AG filed Critical Novartis AG
Publication of AU2001250420A1 publication Critical patent/AU2001250420A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/10Dispersions; Emulsions
    • A61K9/107Emulsions ; Emulsion preconcentrates; Micelles
    • A61K9/1075Microemulsions or submicron emulsions; Preconcentrates or solids thereof; Micelles, e.g. made of phospholipids or block copolymers
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • A61K38/04Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/12Cyclic peptides, e.g. bacitracins; Polymyxins; Gramicidins S, C; Tyrocidins A, B or C
    • A61K38/13Cyclosporins
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/14Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605Excipients; Inactive ingredients
    • A61K9/1617Organic compounds, e.g. phospholipids, fats
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/14Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605Excipients; Inactive ingredients
    • A61K9/1629Organic macromolecular compounds
    • A61K9/1652Polysaccharides, e.g. alginate, cellulose derivatives; Cyclodextrin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/02Immunomodulators
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/02Immunomodulators
    • A61P37/06Immunosuppressants, e.g. drugs for graft rejection
AU2001250420A 2000-04-10 2001-04-09 Pharmaceutical compositions Abandoned AU2001250420A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GBGB0008785.8A GB0008785D0 (en) 2000-04-10 2000-04-10 Organic compounds
GB0008785 2000-04-10
PCT/EP2001/004051 WO2001076561A2 (en) 2000-04-10 2001-04-09 Pharmaceutical compositions

Publications (1)

Publication Number Publication Date
AU2001250420A1 true AU2001250420A1 (en) 2001-10-23

Family

ID=9889585

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2001250420A Abandoned AU2001250420A1 (en) 2000-04-10 2001-04-09 Pharmaceutical compositions

Country Status (12)

Country Link
US (3) US20030133984A1 (en)
EP (2) EP1767193A3 (en)
JP (1) JP2003530340A (en)
CN (2) CN1231208C (en)
AU (1) AU2001250420A1 (en)
BR (1) BR0109931A (en)
CA (1) CA2404368C (en)
FR (1) FR2807658A1 (en)
GB (1) GB0008785D0 (en)
IT (1) ITMI20010748A1 (en)
PE (1) PE20020225A1 (en)
WO (1) WO2001076561A2 (en)

Families Citing this family (36)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE10026698A1 (en) 2000-05-30 2001-12-06 Basf Ag Self-emulsifying active ingredient formulation and use of this formulation
US20040018228A1 (en) * 2000-11-06 2004-01-29 Afmedica, Inc. Compositions and methods for reducing scar tissue formation
AR033711A1 (en) * 2001-05-09 2004-01-07 Novartis Ag PHARMACEUTICAL COMPOSITIONS
GB0123400D0 (en) 2001-09-28 2001-11-21 Novartis Ag Organic compounds
JP4387639B2 (en) * 2002-07-16 2009-12-16 久光製薬株式会社 Transdermal absorption preparation
GB2391471B (en) * 2002-08-02 2005-05-04 Satishchandra Punambhai Patel Pharmaceutical compositions
WO2004062643A1 (en) * 2003-01-14 2004-07-29 Lifecycle Pharma A/S Dry dispersions
US20040185068A1 (en) * 2003-03-18 2004-09-23 Zhi-Jian Yu Self-emulsifying compositions, methods of use and preparation
AU2004261163A1 (en) * 2003-07-25 2005-02-10 Wyeth CCI-779 lyophilized formulations
US8025899B2 (en) 2003-08-28 2011-09-27 Abbott Laboratories Solid pharmaceutical dosage form
US8377952B2 (en) 2003-08-28 2013-02-19 Abbott Laboratories Solid pharmaceutical dosage formulation
US20050059583A1 (en) 2003-09-15 2005-03-17 Allergan, Inc. Methods of providing therapeutic effects using cyclosporin components
GB0504950D0 (en) * 2005-03-10 2005-04-20 Novartis Ag Organic compositions
US7276476B2 (en) * 2005-07-13 2007-10-02 Allergan, Inc. Cyclosporin compositions
US7288520B2 (en) * 2005-07-13 2007-10-30 Allergan, Inc. Cyclosporin compositions
US7202209B2 (en) 2005-07-13 2007-04-10 Allergan, Inc. Cyclosporin compositions
US20070015691A1 (en) 2005-07-13 2007-01-18 Allergan, Inc. Cyclosporin compositions
US7297679B2 (en) 2005-07-13 2007-11-20 Allergan, Inc. Cyclosporin compositions
US20070015693A1 (en) * 2005-07-13 2007-01-18 Allergan, Inc. Cyclosporin compositions
US7501393B2 (en) * 2005-07-27 2009-03-10 Allergan, Inc. Pharmaceutical compositions comprising cyclosporins
US9839667B2 (en) 2005-10-14 2017-12-12 Allergan, Inc. Prevention and treatment of ocular side effects with a cyclosporin
US7745400B2 (en) * 2005-10-14 2010-06-29 Gregg Feinerman Prevention and treatment of ocular side effects with a cyclosporin
EP1880715A1 (en) * 2006-07-19 2008-01-23 Abbott GmbH & Co. KG Pharmaceutically acceptable solubilizing composition and pharmaceutical dosage form containing same
PL2131821T3 (en) * 2007-03-07 2018-11-30 Abraxis Bioscience, Llc Nanoparticle comprising rapamycin and albumin as anticancer agent
CN101199836B (en) * 2007-11-07 2011-03-30 安徽省药物研究所 Stage releasing CsA solid tiny milk agent and tiny milk curing method thereof
CU23892B1 (en) * 2007-12-07 2013-04-19 Ct De Investigación Y Desarrollo De Medicamentos Cidem CYCLOSPORINE MICROENCAPSULATED PHARMACEUTICAL COMPOSITION A
MX2011005151A (en) * 2008-11-21 2011-05-30 Boehringer Ingelheim Int Pharmaceutical composition of a potent hcv inhibitor for oral administration.
CA2767692C (en) 2009-07-07 2017-03-07 Boehringer Ingelheim International Gmbh Pharmaceutical composition for a hepatitis c viral protease inhibitor
MX2012003230A (en) * 2009-09-19 2012-04-10 Brian Charles Keller Pharmaceutical compositions of rapamycin.
WO2011139899A2 (en) 2010-05-03 2011-11-10 Teikoku Pharma Usa, Inc. Non-aqueous taxane pro-emulsion formulations and methods of making and using the same
JO3685B1 (en) 2012-10-01 2020-08-27 Teikoku Pharma Usa Inc Non-aqueous taxane nanodispersion formulations and methods of using the same
TW201503912A (en) * 2013-03-19 2015-02-01 Novartis Ag Pharmaceutical compositions comprising everolimus
US10576076B2 (en) 2015-05-20 2020-03-03 Novartis Ag Pharmaceutical combination of everolimus with dactolisib
ITUA20164228A1 (en) * 2016-06-09 2017-12-09 Labomar S R L Self-emulsifying and gastro-resistant fat matrix formulation and relative preparation method
CA3044355A1 (en) 2016-11-23 2018-05-31 Novartis Ag Methods of enhancing immune response with everolimus, dactolisib or both
WO2019157516A1 (en) 2018-02-12 2019-08-15 resTORbio, Inc. Combination therapies

Family Cites Families (39)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR1274354A (en) 1956-03-10 1961-10-27 Surfactants obtained from triglycerides and polyethylene glycol
US3244592A (en) 1962-06-09 1966-04-05 Arai Tadashi Ascomycin and process for its production
ZA737247B (en) 1972-09-29 1975-04-30 Ayerst Mckenna & Harrison Rapamycin and process of preparation
AU609242B2 (en) * 1988-01-29 1991-04-26 Novartis Ag Cyclosporin compositions
GB2222770B (en) 1988-09-16 1992-07-29 Sandoz Ltd Pharmaceutical compositions containing cyclosporins
DE69021833T2 (en) 1989-11-09 1996-03-21 Sandoz Ag Tricyclic compounds containing heteroatoms.
MY110418A (en) 1990-07-02 1998-05-30 Novartis Ag Heteroatoms-containing tricyclic compounds.
PT98990A (en) 1990-09-19 1992-08-31 American Home Prod PROCESS FOR THE PREPARATION OF CARBOXYLIC ACID ESTERS OF RAPAMICIN
CA2095627C (en) * 1990-11-06 1999-01-05 Junzo Seki Stable lyophilized fatty emulsions and a process for the production thereof
US5120842A (en) 1991-04-01 1992-06-09 American Home Products Corporation Silyl ethers of rapamycin
US5100883A (en) 1991-04-08 1992-03-31 American Home Products Corporation Fluorinated esters of rapamycin
US5118678A (en) 1991-04-17 1992-06-02 American Home Products Corporation Carbamates of rapamycin
US5118677A (en) 1991-05-20 1992-06-02 American Home Products Corporation Amide esters of rapamycin
GB9113872D0 (en) 1991-06-27 1991-08-14 Sandoz Ag Improvements in or relating to organic compounds
US5151413A (en) 1991-11-06 1992-09-29 American Home Products Corporation Rapamycin acetals as immunosuppressant and antifungal agents
GB9125660D0 (en) 1991-12-03 1992-01-29 Smithkline Beecham Plc Novel compound
HUT66531A (en) 1992-05-07 1994-12-28 Sandoz Ag Heteroatoms-containing tricyclic compounds, pharmaceutical prepns contg. them and process for producing them
ZA935112B (en) 1992-07-17 1994-02-08 Smithkline Beecham Corp Rapamycin derivatives
US5234140A (en) 1992-07-28 1993-08-10 S. C. Johnson & Son, Inc. Re-useable aerosol container
US5256790A (en) 1992-08-13 1993-10-26 American Home Products Corporation 27-hydroxyrapamycin and derivatives thereof
GB9221220D0 (en) 1992-10-09 1992-11-25 Sandoz Ag Organic componds
US5258389A (en) 1992-11-09 1993-11-02 Merck & Co., Inc. O-aryl, O-alkyl, O-alkenyl and O-alkynylrapamycin derivatives
CA2175215C (en) 1993-11-19 2008-06-03 Yat Sun Or Semisynthetic analogs of rapamycin (macrolides) being immunomodulators
KR0146671B1 (en) * 1994-02-25 1998-08-17 김충환 Cyclosporin-containing powder composition
EP0788346B9 (en) * 1994-03-18 2007-02-14 Supernus Pharmaceuticals, Inc. Emulsified drug delivery systems
RU2119351C1 (en) * 1994-06-01 1998-09-27 Юхан Корпорейшн Cyclosporin-containing immunosuppressive composition and a method of its preparing
IL129547A (en) 1994-10-26 2001-01-11 Novartis Ag Pharmaceutical compositions comprising a macrolide and an acid
US5716642A (en) * 1995-01-10 1998-02-10 Nano Systems L.L.C. Microprecipitation of nanoparticulate pharmaceutical agents using surface active material derived from similar pharmaceutical agents
DE19544507B4 (en) * 1995-11-29 2007-11-15 Novartis Ag Cyclosporin containing preparations
US6306434B1 (en) * 1997-02-12 2001-10-23 Chong Kun Dang Corp. Pharmaceutical composition comprising cyclosporin solid-state microemulsion
NZ328751A (en) * 1997-09-16 1999-01-28 Bernard Charles Sherman Solid medicament containing an anionic surfactant and cyclosporin
US20030216303A1 (en) * 1998-03-06 2003-11-20 Michael Ambuhl Emulsion preconcentrates containing cyclosporin or a macrolide
ID25908A (en) * 1998-03-06 2000-11-09 Novartis Ag EMULSION PRACTONCENTRATES CONTAINING CYCLOSPORINE OR MACROLIDES
DE19819273A1 (en) * 1998-04-30 1999-11-11 Pharmatec International S Giul Pharmaceutical ciclosporin formulation with improved biopharmaceutical properties, increased physical quality and stability as well as processes for its manufacture
KR100336090B1 (en) * 1998-06-27 2002-05-27 윤승원 Solid dispersed preparation of poorly water-soluble drug containing oil, fatty acid or mixture thereof
ATE462417T1 (en) * 1998-08-13 2010-04-15 Cima Labs Inc MICROEMULSIONS AS SOLID DOSE FORMS FOR ORAL ADMINISTRATION
US6395300B1 (en) * 1999-05-27 2002-05-28 Acusphere, Inc. Porous drug matrices and methods of manufacture thereof
AU1043201A (en) * 1999-11-02 2001-05-14 Cipla Limited Cyclosporin formulation
GB0009773D0 (en) * 2000-04-19 2000-06-07 Univ Cardiff Particulate composition

Also Published As

Publication number Publication date
US20060134203A1 (en) 2006-06-22
PE20020225A1 (en) 2002-04-15
EP1272163A2 (en) 2003-01-08
WO2001076561A2 (en) 2001-10-18
CA2404368A1 (en) 2001-10-18
CA2404368C (en) 2011-02-01
CN1422149A (en) 2003-06-04
CN1231208C (en) 2005-12-14
GB0008785D0 (en) 2000-05-31
BR0109931A (en) 2003-05-27
US20100215734A1 (en) 2010-08-26
CN100431600C (en) 2008-11-12
CN1679916A (en) 2005-10-12
EP1767193A3 (en) 2009-01-28
WO2001076561A3 (en) 2002-02-21
FR2807658A1 (en) 2001-10-19
JP2003530340A (en) 2003-10-14
ITMI20010748A1 (en) 2002-10-06
EP1767193A2 (en) 2007-03-28
US20030133984A1 (en) 2003-07-17
ITMI20010748A0 (en) 2001-04-06

Similar Documents

Publication Publication Date Title
AU781269C (en) Pharmaceutical compositions
AU2001250420A1 (en) Pharmaceutical compositions
AU2001274307A1 (en) Pharmaceutical compositions
AU2002313236A1 (en) Medicinal compositions
AU6219601A (en) Pharmaceutical compositions
GB0009584D0 (en) Pharmaceutical compositions
AU2002302147A1 (en) Pharmaceutical composition
AU3556400A (en) Pharmaceutical compositions
AU2002214324A1 (en) Medicinal compositions
AU8576801A (en) Pharmaceutical compositions
AU2001290239A1 (en) Medicinal composition
AU2001273919A1 (en) Pharmaceutical compositions
AU1390002A (en) Pharmaceutical compositions
AU6460400A (en) Pharmaceutical compositions
GB0009613D0 (en) Pharmaceutical compositions
AU6460200A (en) Pharmaceutical compositions
AU4085201A (en) Pharmaceutical composition
AU6460300A (en) Pharmaceutical compositions
AU6460100A (en) Pharmaceutical compositions
AU3586401A (en) Pharmaceutical composition
AU2001278705A1 (en) Pharmaceutical composition
AU2001282541A1 (en) Medicinal compositions
AU2001285737A1 (en) Pharmaceutical compositions
AUPR529701A0 (en) Pharmaceutical composition
AU2002346223A1 (en) Medicinal compositions